Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 2, 2025Frontiers in Cell and Developmental BiologyOpen Access

The tiny giants of regeneration: MSC-derived extracellular vesicles as next-generation therapeutics

View Full Paper
Ask AI
Bookmark
Share

Authors

TZTianhe ZhangLiaoning Provincial People's HospitalLZLiang ZhangUniversity of Science and Technology of ChinaXMXiaoxue MaChinese Academy of Medical Sciences & Peking Union Medical College

Discussion

Loading...

Member takes

Implication

Clinical trials validate the safety of MSC-derived extracellular vesicles, suggesting new approaches for regenerative medicine.

Key Points

  • MSC-derived extracellular vesicles offer advantages like low immunogenicity and efficient biological barrier penetration.
  • Clinical trials with MSC-EVs show promise in treating diseases like COVID-19, stroke, and wound healing.
  • Targeted delivery and standardized production processes remain challenges for clinical applications of MSC-EVs.
  • Interdisciplinary technologies may enhance the use of MSC-EVs in precision medicine and large-scale applications.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/689a0c7be6551bb0af8d0494https://doi.org/10.3389/fcell.2025.1612589
View Full Paper
Ask AI
Bookmark
Share